CDw75/ST6GAL1 Antibody (6A37): sc-70836
- CDw75/ST6GAL1 Antibody (6A37) is a mouse monoclonal IgM provided at 200 µg/ml
- raised against nuclei from Pokeweed mitogen-stimulated peripheral blood lymphocytes of human origin
- recommended for detection of CDw75 of mouse, rat and human origin by IF, IHC(P) and FCM
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CDw75/ST6GAL1 Antibody (6A37). This work is in progress.
QUICK LINKS
SEE ALSO...
ST6GAL1 Antibody (6A37) is a mouse monoclonal IgM antibody that detects ST6GAL1 in mouse, rat, and human samples through applications such as immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). ST6GAL1, also known as CD75, is a crucial sialyltransferase that plays a significant role in modifying cell surface glycoproteins and glycolipids, which is essential for various cellular processes, including tumorigenesis and metastasis. ST6GAL1 catalyzes the transfer of sialic acid to carbohydrate chains on glycoproteins, thereby influencing the expression of cell surface antigens such as CD76 and CDw75. Located primarily in the Golgi apparatus, ST6GAL1 is a type II membrane protein secreted into the extracellular fluid, where ST6GAL1 contributes to generating sialylated antigens that serve as important carbohydrate determinants on the cell surface. Notably, the antigen CDw75, formed through ST6GAL1 action, is predominantly expressed on B and T cells and has been shown to be upregulated in B-cell leukemias, indicating a potential role in carcinogenesis. Anti-ST6GAL1 antibody (6A37) effectively detects ST6GAL1 across multiple species and applications, making anti-ST6GAL1 antibody (6A37) a valuable tool for researchers studying sialylation implications in cancer and immune responses.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CDw75/ST6GAL1 Antibody (6A37) References:
- Glycosyltransferase ST6GAL1 contributes to the regulation of pluripotency in human pluripotent stem cells. | Wang, YC., et al. 2015. Sci Rep. 5: 13317. PMID: 26304831
- The role of DNA methylation in ST6Gal1 expression in gliomas. | Kroes, RA. and Moskal, JR. 2016. Glycobiology. 26: 1271-1283. PMID: 27510958
- Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer. | Wichert, B., et al. 2018. Glycobiology. 28: 898-903. PMID: 30016515
- Assembly of B4GALT1/ST6GAL1 heteromers in the Golgi membranes involves lateral interactions via highly charged surface domains. | Khoder-Agha, F., et al. 2019. J Biol Chem. 294: 14383-14393. PMID: 31395657
- Loss of core fucosylation in both ST6GAL1 and its substrate enhances glycoprotein sialylation in mice. | Huang, G., et al. 2020. Biochem J. 477: 1179-1201. PMID: 32141499
- ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma. | Myojin, Y., et al. 2021. Clin Cancer Res. 27: 1150-1161. PMID: 33288659
- High-Risk HPV16 E6 Activates the cGMP/PKG Pathway Through Glycosyltransferase ST6GAL1 in Cervical Cancer Cells. | Wang, J., et al. 2021. Front Oncol. 11: 716246. PMID: 34745942
- N-linked α2,6-sialylation of integrin β1 by the sialyltransferase ST6Gal1 promotes cell proliferation and stemness in gestational trophoblastic disease. | Liu, J., et al. 2024. Placenta. 149: 18-28. PMID: 38490094
- The pro-inflammatory cytokines IL-1β and IL-6 promote upregulation of the ST6GAL1 sialyltransferase in pancreatic cancer cells. | Silva, AD., et al. 2024. J Biol Chem. 300: 107752. PMID: 39260693
- Multi-omics reveals that ST6GAL1 promotes colorectal cancer progression through LGALS3BP sialylation. | Shi, Y., et al. 2025. Biomol Biomed.. PMID: 39937175
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CDw75/ST6GAL1 Antibody (6A37) | sc-70836 | 200 µg/ml | $322.00 |